The Effect of Exercise on Gut Microbiota in Type 2 Diabetic Patients

Lifestyle Intervention in Patients With Diabetes Type 2 and the Association With the Gut Microbiota

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03380338

Enrollment

Registered

2017-12-21

Start date

2016-05-11

Completion date

2017-06-29

Last updated

2019-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Sensitivity/Resistance, Type 2 Diabetes Mellitus

Keywords

Gut microbiota

Brief summary

To investigate whether targeted lifestyle intervention (exercise), induces a change in intestinal fecal microbiota related to improved glycemic control and systemic inflammation in patients with DM type 2.

Detailed description

Diet and exercise are the most beneficial lifestyle interventions in patients with diabetes mellitus (DM) type 2, causing an increase in glucose tolerance. One of the mechanisms through which these treatment modalities work might be explained through changes in the gut microbiota. Recent studies show that the chronic inflammatory status causing insulin resistance in DM type 2, is triggered by an increase in circulating bacterial lipopolysaccharide (LPS). Strict lifestyle intervention, such as exercise, so called Diabetes Bootcamp (DB), may manipulate the gut microbiota, reducing circulating LPS, causing an improvement of the insulin-mediated

Interventions

BEHAVIORALCombined aerobic and strength exercise

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Subjects must meet the criteria for diabetes type 2 (a random blood sugar of \> 11.1 mmol/L and/or a fasting blood sugar lever of \>7.0 mmol/L and/or a blood sugar of \>11.1 mmol/L two hours after an oral glucose tolerance test and/or an HbA1c level of \>47 mmol/mol). * Male or female (post-menopausal) * Age above 45 years and below 70 years * BMI \>30 kg/m2 * HbA1c \< 80 mmol/mol or \< 8,6% Subjects must use metformin * Stable medication use * Stable tension regulation (with or without medication) * Subjects should be able to give informed consent

Exclusion criteria

* A history of cardiovascular event (Cerebrovascular event, myocardial infarction or pacemaker implantation) * Severe-very severe lung emphysema (GOLD stage III-IV) * Use of any antibiotics or proton pump inhibitor (PPI) in the past three months * Use of any other antidiabetic medication besides metformin (e.g. SU-derivates, insulin) * Use of a platelet inhibitor or cumarin derivate during * Subjects participated in a lifestyle programme in the past 6 months (diet or exercise)

Design outcomes

Primary

Measure	Time frame	Description
Changes in gut microbiota composition upon exercise	At baseline, after 7 weeks, after 13 weeks	alfa-diversity, beta-diversity
Change in insulin senistivity	Before and after exercise, i.e. from first visit (0 weeks) untill last visit (13 weeks)	Rate of disappearance measured by the hyperinsulinemic-euglycemic clamp with stable glucose isotopes.
Change in capillary recruitment	Before and after exercise, i.e. from first visit (0 weeks) untill last visit (13 weeks)	Insulin-induced capillary recruitment in skeletal muscle and heart

Secondary

Measure	Time frame	Description
Changes in resting energy expenditure	Before and after exercise	Indirect calorimetry
Changes in continous cardiovascular monitoring	Before and after exercise	—

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026